Ionis Pharmaceuticals (NasdaqGS:IONS) Q3 2025 Earnings Call October 29, 2025 11:30 AM ET Company ParticipantsKyle Jenne - Chief Global Product Strategy OfficerRichard Geary - Chief Development OfficerBeth Hougen - CFOWade Walke - SVPGary Nachman - Managing Director of BioPharma/Biotech Equity ResearchMike Ulz - Executive Director of Biotechnology Equity ResearchGena Wang - Managing Director and Biotech Equity ResearchBrett Monia - CEOConference Call ParticipantsMyles Minter - Biotech Equity Research Analyst ...

Q3:2025 Business Update and Financial Results October 29, 2025 Nasdaq: IONS 1 On Today's Earnings Call Eugene Schneider, M.D. Chief Clinical Development Officer Eric Swayze, Ph.D. Executive Vice President, Research 2 Richard Geary, Ph.D. Chief Development Officer Kyle Jenne Chief Global Product Strategy Officer Beth Hougen Chief Financial Officer Forward-Looking Statements This presentation includes forward-looking statements regarding our business, financial guidance and the therapeutic and commercial pote ...

2 Ionis Leadership Here Today Innovation Day 2025: Accelerating Growth through Life-Changing Medicines OCTOBER 7, 2025 | Nasdaq: IONS Forward-Looking Statements This presentation includes forward-looking statements regarding our business, financial guidance and the therapeutic and commercial potential of our commercial medicines, additional medicines in development and technologies and our expectations regarding development and regulatory milestones. Any statement describing Ionis' goals, expectations, fina ...

Q2:2025 Business Update and Financial Results July 30, 2025 Nasdaq: IONS 1 On Today's Earnings Call Eugene Schneider, M.D. Chief Clinical Development Officer Eric Swayze, Ph.D. Executive Vice President, Research 2 Brett Monia, Ph.D. Chief Executive Officer Kyle Jenne Chief Global Product Strategy Officer In this presentation, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries. Ionis Pharmaceuticals® is a registered trademark ...